The MAGNOLIA study is a double-blind phase II trial which evaluates the safety and efficacy of antigen-specific cancer immunotherapy with recMAGE-A3 + AS15 in patients with muscle-invasive bladder cancer. This non-commercial study is the first European bladder cancer study sponsored by the EAU Research Foundation, and the only European study evaluating antigen-specific immunotherapy in patients after cystectomy. The study has started in 36 sites in around Europe. New sites from Romania, Ukraine and Russia will be initiated in the next month.
Share this on your favourite network: